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Abstract
Background: A new autoantibody (termed NMO-IgG, or AQP4-Ab) has recently been described in patients with
neuromyelitis optica (NMO) and its formes frustes, longitudinally extensive transverse myelitis (LETM) and recurrent optic
neuritis (rON). However, AQP4-Ab has been found also in patients with co-existing rheumatic diseases such as systemic
lupus erythematosus (SLE) or Sjo¨gren’s syndrome (SS), conditions which are characterized by broad, polyspecific B cell
activation.
Objectives: In this study, we aimed at evaluating the syndrome specificity and frequency of AQP4-Ab in patients with
rheumatic diseases and neurological symptoms.
Methods: For this purpose, serum samples from 109 neurological patients with established connective tissue disorders
(CTD) (n ¼ 54), possible CTD (n ¼ 42), or vasculitis (n ¼ 13) were analysed for the presence of AQP4-Ab by a cell-
based assay employing recombinant human AQP4.
Results: AQP4-Ab was detectable in 31/40 (78%) patients with CTD and NMO spectrum disorders (median titre,
1:1000) but in none of the samples obtained from patients with CTD or vasculitis and neurological disorders other than
NMO, LETM, or rON (n ¼ 69).
Conclusion: The high syndrome specificity of the antibody for neuromyelitis optica spectrum disorders (NMOSDs) in
patients with CTD supports the concept of AQP4-Ab being involved in the pathogenesis of these neurological condi-
tions, and argues against AQP4-Ab simply being part of the polyclonal B cell activation generally associated with rheu-
matic diseases. Moreover, the finding that AQP4-Ab is present in patients with CTD and co-existing NMOSD with
approximately the same frequency as in patients without CTD strengthens the case of CTD and AQP4-Ab positive
NMOSD representing two co-existing yet distinct entities in the majority of patients.
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Introduction
Neuromyelitis optica (NMO) is a very rare inﬂamma-
tory disorder of the central nervous system (CNS) of
putative autoimmune aetiology, which mainly aﬀects
the optic nerves and spinal cord.1 Recent studies dem-
onstrated that NMO and its formes frustes, longitudi-
nally extensive transverse myelitis (LETM)2 and
recurrent optic neuritis (rON),3,4 are associated with
the presence of a newly detected serum reactivity to
structures adjacent to the CNS microvasculature and
pia mater in 60–80% of cases (called NMO-IgG).5,6
This antibody was later shown to target aquaporin-4
(AQP4), the most abundant water channel in the
CNS.7,8
Interestingly, AQP4-Ab was found also in a subset
of NMO and LETM patients with co-existing connec-
tive tissue disorders (CTDs) such as systemic lupus ery-
thematosus (SLE) or Sjo¨gren’s syndrome (SS).9
However, CTDs are usually associated with a broad
repertoire of autoantibodies, many of which are of no
proven pathogenic impact. AQP4-Ab could be part of
that polyclonal B-cell response in patients with CTD
rather than being pathogenetically related to the neu-
rological syndrome.
Strong evidence for a role of AQP4-Ab in the path-
ogenesis of NMO and LETM/rON in patients with
CTD would come from the demonstration that the
antibody is present only in patients with CTD and
NMO or LETM/rON but not in patients with CTD
and neurological disorders other than NMO and
LETM/rON.
Here we report on the AQP4-Ab serostatus of 109
patients with established or suspected rheumatic dis-
eases and co-existing neurological disorders.
Patients and methods
Inclusion criterion was the presence of SLE, SS, sys-
temic scleroderma, polymyositis/dermatomyositis,
Sharp syndrome, or vasculitis at the time of neurolog-
ical presentation, or of autoantibodies usually associ-
ated with those disorders. Exclusion criterion was the
presence of co-existing conditions that could suﬃciently
explain the neurological syndrome, such as infections,
or stroke due to well established causes other than
CTD. Group I consisted of 54 patients with deﬁnite
CTD and neurological involvement (see Table 1 for
details). CTD in this group comprised SLE (n ¼ 41),
primary SS (6), SLE with secondary SS (2), systemic
sclerosis (1), systemic sclerosis with SS (1), scleroderma
en coup-de-sabre (1), CREST syndrome (1), and Sharp
syndrome with biopsy proven polymyositis (1). Group
II consisted of 42 patients with various neurological
syndromes (Table 1), who were positive for auto-anti-
bodies usually associated with CTD but who did not
fulﬁl the formal criteria for any CTD based on the data
available for analysis. Anti-nuclear antibodies were pre-
sent in 40/42, SS-A and/or SS-B in 13, cardiolipin and
anti-ß2-glycoprotein antibodies in 16, double stranded
DNA antibodies in nine, ribonucleoprotein antibodies
in nine, lupus anticoagulans in three, Scl-70 antibodies
in two, histon antibodies in three, and centromer anti-
bodies in ﬁve; three patients were, in addition, positive
for rheumatoid factor and one for single strand DNA
antibodies and circulating immune complexes. Further
features of CTD such as Raynaud’s phenomenon, sicca
symptoms, polyserositis, nephritis, or arthralgia were
present in 16 patients; in addition, Coombs’ positive
anaemia was reported in one, and other haematological
disturbances in seven. Group III consisted of 13
patients with vasculitis. Seven patients had primary
arteritis of the CNS (PACNS), four giant cell arteritis,
one leukocytoclastic vasculitis, and one post-infectious
systemic vasculitis involving the CNS.
All SLE patients fulﬁlled the American College of
Rheumatology (ACR) criteria.10,11 SS was diagnosed
according to Vitali et al.12 and scleroderma according
to Masi et al.13 The diagnosis of PACNS was estab-
lished according to Moore and Richardson14 in 5/7
cases and according to Calabrese and Mallek15 in two
cases. NMO was diagnosed according to Wingerchuk’s
2006 criteria.1 LETM was deﬁned as myelitis extending
over three or more vertebral segments. NMOSD fol-
lowed a relapsing course in 36 patients and was mono-
phasic in four.
Samples were tested for AQP4-Ab in an anonymized
fashion at the Department of Neurology, University of
Heidelberg by means an indirect immunoﬂuorescence
assay employing human full length AQP4 expressed
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in HEK293 cells.16 Brieﬂy, formalin-ﬁxed AQP4-trans-
fected HEK293 cells, which were provided immobilized
on microscopy slides, were incubated with serum or CSF
diluted 1:10 in 1% bovine serum albumin and, after
washing in PBS, with a goat anti-human IgG antibody
conjugated to ﬂuorescein isothiocyanate (FITC). After
ﬁnal washing in PBS and mounting in glycerol contain-
ing an anti-fading agent, cells were analysed for bound
AQP4-IgG on a Nikon 90i ﬂuorescence microscope
(Nikon Imaging Center, University of Heidelberg,
Germany). This assay was previously shown to have a
sensitivity of 78% and a speciﬁcity of 100% (n ¼ 151).16
All patients were of Caucasian origin. Sex ratios in the
various diagnostic groups as well as median age at blood
sampling are given in Table 1.
Results
AQP4-Ab was detectable in 20/27 (74%) samples from
patients with deﬁnite or possible rheumatic diseases and
NMO, in 11/13 (85%) samples from patients with rheu-
matic diseases and LETM or rON, but in none out of
69 samples obtained from patients with rheumatic dis-
eases and neurological disorders other than NMO,
LETM, or rON (p< 0.00001; Fisher exact test).
Neurological disorders or symptoms in the latter
group included longitudinally non-extensive transverse
myelitis, demyelinating disease of the brain, brain
infarction, (micro)bleedings of the brain, aseptic men-
ingitis, seizures, trigeminal neuralgia, polyneuropathy,
mononeuritis, ataxia, depression and other psychiatric
syndromes, neuropsychological disorders, myositis, and
headache.
The frequency of AQP4-Ab was 84.6% in patients
with SLE and NMO or LETM/rON and 62.5% in
patients with other CTD and NMO or LETM.
AQP4-Ab serum titres in patients with NMOSD and
CTD (median, 1:1000; range, 1:50–1:10.000; n ¼ 19;
deﬁnite CTD in 16, possible CTD in three) did not
diﬀer signiﬁcantly from those in a group of unselected
control patients with NMOSD but no CTD (median,
1:1000; range, 1:50–1:12.500; n ¼ 20). AQP4-Ab
was positive in 78% (28/36) of the relapsing cases,
and in 75% (3/4) of the monophasic cases. The
median maximum longitudinal extension of spinal
cord lesions did not diﬀer between AQP4-Ab positive
and AQP4-Ab negative NMOSD patients (5 [range,
3–19] and 5.5 [3 to ‘entire spinal cord’], respectively),
nor did the median total number of relapses (4.5 and 6,
respectively).
Cranial lesions as detected by MRI were present in
17/40 (43%) NMOSD patients, with no signiﬁcant dif-
ference between AQP4-Ab positive (12/31) and nega-
tive cases (5/9). Brain stem MRI lesions were noted in
6/31 AQP4-Ab positive NMOSD patients (19%) and in
3/9 AQP4-Ab negative NMOSD patients (33%), and
were situated in the medulla oblongata in six patients
(AQP4-Ab positive in ﬁve) and in the pons in two
(AQP4-Ab positive in one). Brain stem involvement
was also suspected in some additional AQP4-Ab posi-
tive patients based on clinical presentation (vomiting
and tonic ﬁts in one, and diplopia in two), though
Table 1. Rheumatic diagnoses and neurological syndromes, epidemiological data and serum AQP4-Ab results from neurological
patients with established or possible connective tissue disorders or vasculitis
Diagnostic groups and neurolog-
ical syndromes N Sex (m:f) Age (median, range) AQP4-AbN (%)
Definite CTD
NMO spectrum disorders
NMO
LETM
rON
Syndromes other than NMO/
LETM/rON
54
21
15
5
1
33
1:20 46 (16–75) 16 (30)
16 (76)
10 (67)
5 (100)
1 (100)
0 (0)
Possible CTD
NMO spectrum disorders
NMO
LETM
rON
Syndromes other than NMO/
LETM/rON
42
19
12
6
1
23
1:3.6 45 (21–79) 15 (36)
15 (79)
10 (83)
4 (67)
1 (100)
0 (0)
Vasculitis 13 1:12 52 (35–88) 0 (0)
NMO: neuromyelitis optica, LETM: longitudinally extensive transverse myelitis, rON: recurrent optic neuritis.
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MRI was negative. In two patients with brain stem
lesions, both of which were AQP4-Ab positive, addi-
tional lesions in the diencephalon (thalamus in two,
hypothalamus in one), mesencephalon (cerebral pedun-
cle), basal ganglia (capsula interna), and cerebellar
peduncles were observed; in addition, cerebellar lesions
were evident in one of them. Supratentorial white
matter MRI lesions were noted in 32% (10/31) of the
AQP4-Ab positive and 22% (2/9) of the AQP4-Ab neg-
ative NMOSD patients. Periventricular, juxtacortical,
or callosal lesions were reported in six of the patients
(AQP4-Ab positive in ﬁve). Extra-opticospinal neuro-
logical manifestations, which are normally absent in
patients with NMO,20 were documented in six AQP4-
Ab positive patients and one AQP4-Ab negative
patient. These manifestations included psychosis in
two (though steroid associated in one of them), cogni-
tive deﬁcits in one, seizures in one, transient ischemic
attacks in two, polyneuropathy in two, and polymyosi-
tis in one. Three NMOSD patients (AQP4-Ab positive
in two) had co-existing acetylcholine receptor antibody
positive myasthenia gravis, one of which in addition
suﬀered from coeliac disease.
Thryoid stimulating hormone receptor antibody
positive autoimmune thyroiditis with hyperthyroidism
(Grave’s disease) was present in four patients (AQP4-
Ab positive in three) and Hashimoto thyroiditis with
hypothyroidism in two (both AQP4-Ab positive).
In two additional patients, thyroglobulin or thyroid
peroxidase antibodies respectively, but no evidence
for thyroid dysfunction, were found, and in two further
patients hypothyrodism was noted at least once but
anti-thyroid antibodies had not been determined (all
AQP4-Ab positive).
One AQP4-Ab positive patient with NMOSD in
group I and three AQP4-Ab positive patients with
NMOSD in group II were positive for perinuclear anti-
neutrophil cytoplasmic antibodies (pANCA) (myelo-
peroxidase-speciﬁc pANCA in two, pANCA of
unknown speciﬁcity in two); in contrast, 26 other
patients with NMOSD (AQP4-Ab positive in 20) were
negative for ANCAs. A strong female preponderance
was evident both in the NMOSD (sex ratio, m:f ¼
1:12.3) and in the non-NMOSD (m:f ¼ 1:4.6) group
(p ¼ 0.23), with no signiﬁcant diﬀerence between
AQP4-Ab positive (female in 97%) and AQP4-Ab neg-
ative NMOSD patients (female in 78%). See Table 1
for further results.
Discussion
We found that AQP4-Ab seropositivity in patients with
CTDs such as SLE or SS and co-existing neurological
disorders is restricted to those with NMO, LETM, or
rON. The high syndrome speciﬁcity of AQP4-Ab in
patients with neuropsychiatric CTD argues strongly
against the antibody being simply part of the CTD-
associated spectrum of non-tissue speciﬁc autoantibo-
dies but suggests that it is linked to the pathogenesis of
NMO, LETM, or rON in those patients. In previous
studies, we and others had already demonstrated a lack
of AQP4-Ab seropositivity in patients with CTD but no
neurological disease (n ¼ 45).8,9,17 We also found that
both the rate of AQP4-Ab seropositivity and the
median AQP4-Ab serum titres do not diﬀer signiﬁ-
cantly between patients with NMOSD and co-existing
CTD and patients with NMO but no CTD.
Our results corroborate ﬁndings from two smaller
studies. Pittock et al. reported a lack of AQP4-Ab in
eight patients with CTD and neurological syndromes
other than NMOSD from an American cohort and in
six patients from a French cohort.9 In this study, a non-
AQP4-speciﬁc immunohistochemical assay employing
adult mouse cerebellum tissue sections as substrate
was used to detect AQP4-Ab. In a second, independent
study, Wandinger et al. very recently reported a lack of
AQP4-Ab in a mixed British–German cohort with neu-
rological syndromes but not NMOSD.17 This study,
which employed the same recombinant assay as used
here, included 41 patients with CTD and neurological
syndromes other than NMOSD, but only three patients
with CTD and NMO (compared with 27 in the present
study).
The ﬁnding of AQP4-Ab in a subset of patients with
CTD and NMO, LETM, or rON identiﬁes these cases
as part of the newly described spectrum of autoimmune
AQP4-channelopathies.7,18,19 Future trials on neuro-
logical involvement in CTD have to take into account
that AQP4-Ab positive patients may represent a dis-
tinct subgroup with diﬀerential pathogenesis and treat-
ment response. Similarly, this ﬁnding has implications
for everyday clinical practice. AQP4-Ab positive
LETM or rON usually takes a relapsing course and
confers a high risk of conversion to NMO, which, if
untreated, often results in irreversible blindness and
immobility within a short time.2,4,20 Although no con-
trolled treatment trials exist in NMO due to the rarity
of the disorder, long term immunosuppression, e.g.
with azathioprine or rituximab, is thought to be crucial
in AQP4-Ab positive patients, and plasma exchange
seems to be beneﬁcial for the treatment of acute
relapses.21–25
The reason why AQP4-Ab positive NMO/LETM is
frequently associated with CTD is unclear. It has been
speculated that the co-existence of the two disorders in
the same patient might reﬂect a general autoimmune
predisposition. The concept of coexisting independent,
antibody-mediated autoimmune disorders in the same
patient is further supported by the association of AQP4-
Ab positive NMOSD with autoimmune conditions such
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as Grave’s disease, myasthenia gravis, or coeliac disease, as
observed in this study as well as in previous ones.26–30
In addition, CTD-induced tissue damage might well
promote AQP4-Ab-induced pathology. There is
increasing evidence for a direct impact of AQP4-Ab
in the immunopathogenesis of NMO/LETM.18,19,31–33
Brieﬂy, the antibody is thought to confer tissue damage
by complement activation and induction of a cellular
immune response.31,32,34–38 However, several ﬁndings
indicate that AQP4-Ab may not be suﬃcient to cause
CNS disease on its own. First, AQP4-Ab remains
detectable in patients with NMO during remission,
partly at high titres,39 and is even detectable many
years prior to disease onset in some patients.40,41
Secondly, in animal models of NMO, passive transfer
of the antibody into rodents had no eﬀect unless dis-
ruption of the blood–brain barrier or brain inﬂamma-
tion was induced.31,32,42
Importantly, aquaporin-4, the target antigen of
AQP4-Ab, is an integral constituent of the blood–brain
barrier. The protein is concentrated in the astrocytic end-
feet sealing the brain parenchyma against the brain vas-
culature. Vascular damage induced by CTD-associated
vasculitis might thus both render AQP4 accessible to
AQP4-Ab and, in addition, create the inﬂammatory
environment required for induction of the AQP4-
Ab-mediated inﬂammatory cascade. Interestingly, four
AQP4-Ab positive patients with NMO/LETM were pos-
itive for pANCA, antibodies frequently associated with
vasculitis, in the present study.
It should be underlined, however, that CTD, though
a possible promoter, is not a prerequisite of disease
activity in NMO. Pittock et al.9 systematically investi-
gated the frequency of ANA as a sensitive and early
marker of CTD associated autoimmunity, and could
demonstrate a lack of ANA positivity in around 40%
of AQP4-Ab positive NMOSD patients. Accordingly,
the onset of NMOSD preceded the occurrence of clini-
cal or serological signs of CTD related autoimmunity in
at least ﬁve of our patients, who only later in the disease
course developed SLE (n¼ 3; AQP4-Ab positive in two)
or SS (n ¼ 2; AQP4-Ab positive in one). Moreover, the
priority of CTD in time noted in many patients does not
necessarily imply a causal relationship. Instead, at least
in patients with SLE, it might simply reﬂect the dif-
ferential peaks of onset of the two conditions (30 years
of age in SLE,43 40 in relapsing NMO20).
Importantly, 9/39 patients with NMOSD were neg-
ative for AQP4-Ab in our study, suggesting that
NMOSD might be aetiologically heterogeneous. In a
previous study, we found AQP4-Ab in 95/96 serum
samples that were obtained during remission and
under treatment with immunosuppressants such as aza-
thioprine, rituximab, cyclophosphamide, mitoxantrone,
or dexamethasone, rendering it unlikely that AQP4-Ab
seronegativity in those nine patients was caused by
treatment eﬀects.39 Alternatively, tissue damage might
be caused by CTD-mediated mechanisms (e.g. vasculi-
tis) in those patients. Moreover, so far unknown auto-
antibodies might play a role, as indicated by the fact
that plasma exchange was found to be beneﬁcial also in
some AQP4-Ab negative patients in a recent study.44
Seven patients had extra-opticospinal disorders such
as PNP or seizures, which are not usually associated
with AQP4-autoimmunity. The presence of extra-
opticospinal signs and symptoms should prompt phy-
sicians to check for co-existing CTD.
Given the number of centres involved in this study,
we cannot fully exclude that some sort of sampling bias
might have inﬂuenced the data on AQP4-Ab frequency
in CTD and NMO spectrum disorders. However, this
study did not primarily aim at assessing the frequency
of AQP4-Ab but the syndrome speciﬁcity of this new
antibody in patients with CTD. Moreover, the fre-
quency found in this study (77%) is in good accordance
with data from two smaller previous studies.9,17
It is of note that antibodies to AQP4 in patients with
CTD and NMO/LETMwere investigated by means of a
recombinant assay instead of immunohistochemistry
(IHC) in this study. Recombinant assays have repeat-
edly been demonstrated to be more sensitive and slightly
more speciﬁc than IHC.16,35,45–48 The test used in this
study had a 12.5% higher sensitivity when compared
with standard IHC on adult mouse cerebellum sec-
tions and a speciﬁcity of 100% (n ¼ 151).16
In conclusion, our data demonstrates that AQP4-Ab
is highly speciﬁc for NMO/LETM in patients with
CTD. This ﬁnding strengthens the case of AQP4-Ab
being involved in the pathogenesis of NMO/LETM
in patients with CTD. AQP4-Ab testing should be per-
formed in all patients with CTD presenting with signs
and symptoms suggestive of NMO, LETM, or ON.
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